Patents Assigned to Enanta Pharmaceuticals, Inc.
  • Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 10597391
    Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 24, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jing He, Guoqiang Wang, Ruichao Shen, Xuechao Xing, Bin Wang, Jun Ma, Yat Sun Or
  • Process for preparation of sulfonylurea bile acid derivatives
    Patent number: 10584145
    Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 10, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yong He, Peng Dai, Guoyou Xu, Bin Wang, Jiang Long, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 10570153
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 25, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 10538532
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 21, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xiaowen Peng, Yat Sun Or
  • Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10519191
    Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 31, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Ruichao Shen, Peng Dai, Jiang Long, Xuechao Xing, Guoqiang Wang
  • Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
    Patent number: 10501422
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 10, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Andrew Hague, Matthew Ronsheim
  • Bile acid derivatives as FXR agonists and methods of use thereof
    Patent number: 10472386
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10457703
    Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: October 29, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10450301
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 22, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • Isoxazole analogs as FXR agonists and methods of use thereof
    Patent number: 10450306
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: October 22, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jun Ma, Guoqiang Wang, Bin Wang, Xuechao Xing, Ruichao Shen, Jing He, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 10442788
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 15, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Hui Cao, Wei Li, Jorden Kass, Xuri Gao, Xiaowen Peng, Meizhong Jin, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 10428070
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 1, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Xiaowen Peng, Wei Li, Jorden Kass, Hui Cao, Byung-Chul Suh, Yat Sun Or
  • Hepatitis C virus inhibitors
    Patent number: 10407445
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: September 10, 2019
    Assignees: Enanta Pharmaceuticals, Inc., Novartis AG
    Inventors: Yao-Ling Qiu, Hui Cao, Xiaowen Peng, Xuri Gao, Yat Sun Or, Zachary Kevin Sweeney
  • Heteroaryldiazepine derivatives as RSV inhibitors
    Patent number: 10398706
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 3, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Yat Sun Or
  • Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10364267
    Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: July 30, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Guoyou Xu, Peng Dai, Ruichao Shen, Xuechao Xing, Jing He
  • Processes for the preparation of benzodiazepine derivatives
    Patent number: 10358441
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: July 23, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Brian C. Shook, Yat Sun Or
  • Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10323061
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 18, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Jing He, Guoqiang Wang, Xuechao Xing
  • Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10323060
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 18, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Jing He
  • Hepatitis B antiviral agents
    Patent number: 10301255
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 28, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xuri Gao, Xiaowen Peng, Yat Sun Or
  • Hepatitis B antiviral agents
    Patent number: 10280175
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z—R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: May 7, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Meizhong Jin, Jorden Kass, Hui Cao, Xuri Gao, Wei Li, Xiaowen Peng, Yao-Ling Qiu